DAX6.281-1,8%  Dow12.420-1,3%  Euro1,23950,2% 
ESt502.116-2,0%  Nas2.837-1,2%  Öl103,40,2% 
TDax751,1-1,8%  Nikkei8.543-1,1%  Gold1.561-0,1% 
Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)News + AdhocBilanz/GuVTermineZertifikateDepot
Times + SalesChart-AnalyseAnalysenDividende/HVProfilOptionsscheineWatchlist
BörsenplätzeChartvergleichKurszieleVergleichInsidertradesKnock-outsmyHome
OrderbuchRealtime StuttgartRSS FeedAnalyseim ForumFondsSenden/Drucken
HistorischRealtime PushmyNews neu IR-DatenAnleihen
handeln

16.12.2011 14:00

Senden

Molycorp Secures Government Approval To Conduct Heavy Rare Earth Exploratory Drilling

Pfizer zu myNews hinzufügen Was ist das?


Molycorp, Inc. (NYSE: MCP) today announced that it has been granted authorization from the U.S. Bureau of Land Management to commence exploratory drilling at an occurrence of heavy rare earths located near its flagship rare earth manufacturing facility at Mountain Pass, California.

"This is an important milestone in our heavy rare earth strategy, and we expect to begin drilling immediately,” said Mark A. Smith, Molycorp's President and Chief Executive Officer. "We anticipate results from the drilling program in the second quarter of 2012. I’d also like to compliment the Bureau of Land Management and the U.S. Department of Interior for their thorough and efficient review of our drilling Notice."

Preliminary exploration at the site has shown rare earth mineralization with an average ore grade of approximately four percent and a relatively high percentage of heavy rare earths, such as terbium, dysprosium, europium and samarium, as well as relatively high percentages of yttrium, neodymium, and praseodymium.

About Molycorp, Inc.

With offices in the U.S., Europe, and Japan, Molycorp, Inc. is the only U.S-based company that is fully integrated across the rare earth mine-to-magnets supply chain. In addition to its current production of REO at its flagship rare earth mine and processing facility at Mountain Pass, California, the Company produces rare earth metals, rare earth alloys (such as neodymium-iron-boron and samarium-cobalt alloys) and rare metals such as niobium and tantalum. The rare earths and rare metals Molycorp produces are critical inputs in existing and emerging applications including: clean energy technologies, such as hybrid and electric vehicles and wind power turbines; multiple high-tech uses, including fiber optics, lasers and hard disk drives; numerous defense applications, such as guidance and control systems and global positioning systems; advanced water treatment technology for use in industrial, military and outdoor recreation applications; and other technologies. For more information please visit www.molycorp.com

Safe Harbor Statement Regarding Forward-Looking Statements

This release contains forward-looking statements that represent Molycorp’s beliefs, projections, and predictions about future events or future performance. Forward-looking statements can be identified by terminology such as "may,” "will,” "would,” "could,” "should,” "expect,” "intend,” "plan,” "anticipate,” "believe,” "estimate,” "predict,” "potential,” "continue” or the negative of these terms or other similar expressions or phrases. These forward-looking statements are necessarily subjective and involve known and unknown risks, uncertainties and other important factors that could cause Molycorp’s actual results, performance or achievements or industry results to differ materially from any future results, performance or achievement described in or implied by such statements.

Factors that may cause actual results to differ materially from expected results described in forward-looking statements include, but are not limited to: Molycorp’s ability to secure additional capital to implement its business plans; Molycorp’s ability to complete its initial modernization and expansion efforts, including the accelerated start-up of the Mountain Pass facility, which management refers to as Project Phoenix Phase 1, and the second phase capacity expansion plan, which management refer to as Project Phoenix Phase 2, and reach full planned production rates for REOs and other planned downstream products; the final costs of the Project Phoenix Phase 1, including with accelerated start-up of the Mountain Pass facility, and Project Phoenix Phase 2, which may differ from estimated costs; uncertainties associated with Molycorp’s reserve estimates and non-reserve deposit information; uncertainties regarding the results of exploratory drilling programs; uncertainties regarding global supply and demand for rare earths materials; Molycorp’s ability to successfully integrate recently acquired businesses; completion of the formation of the proposed sintered NdFeB rare earth magnet joint venture, which remains subject to the satisfaction of customary closing conditions; the proposed sintered NdFeB rare earth magnet joint venture’s ability to successfully manufacture magnets within its expected timeframe; Molycorp’s ability to maintain appropriate relations with unions and employees; Molycorp’s ability to successfully implement its "mine-to-magnets” strategy; environmental laws, regulations and permits affecting Molycorp’s business, directly and indirectly, including, among others, those relating to mine reclamation and restoration, climate change, emissions to the air and water and human exposure to hazardous substances used, released or disposed of by Molycorp; and uncertainties associated with unanticipated geological conditions related to mining.

For more information regarding these and other risks and uncertainties that Molycorp may face, see the section entitled "Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2010 and of the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2011. Any forward-looking statement contained in this press release or the Annual Report on Form 10-K or the Quarterly Report on Form 10-Q reflects Molycorp’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Molycorp’s operations, operating results, growth strategy and liquidity. You should not place undue reliance on these forward-looking statements because such statements speak only as to the date when made. Molycorp assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future, except as otherwise required by applicable law.

Kommentare zu diesem Artikel

Geben Sie jetzt einen Kommentar zu diesem Artikel ab.
 Kommentar hinzufügen 
  • Relevant
  • Alle
  • vom Unternehmen
  • Sprache:
  • Alle
  • DE
  • EN
  • Sortieren:
  • Datum
  • meistgelesen
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar
Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen
Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen
vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Pfizer Inc. zu myNews hinzufügen Was ist das?
  • Alle
  • Buy
  • Hold
  • Sell
10.05.12Pfizer buyUBS AG
03.05.12Pfizer equal-weightBarclays Capital
03.05.12Pfizer buyUBS AG
03.05.12Pfizer overweightJP Morgan Chase & Co.
02.05.12Pfizer haltenIndependent Research GmbH
10.05.12Pfizer buyUBS AG
03.05.12Pfizer buyUBS AG
03.05.12Pfizer overweightJP Morgan Chase & Co.
02.05.12Pfizer outperformSanford C. Bernstein and Co., Inc.
24.04.12Pfizer buyJefferies & Company Inc.
03.05.12Pfizer equal-weightBarclays Capital
02.05.12Pfizer haltenIndependent Research GmbH
24.04.12Pfizer haltenIndependent Research GmbH
20.04.12Pfizer haltenIndependent Research GmbH
04.04.12Pfizer haltenIndependent Research GmbH
10.01.12Pfizer verkaufenHamburger Sparkasse AG (Haspa)
07.05.10King Pharmaceuticals neues KurszielGoldman Sachs Group Inc.
26.04.10King Pharmaceuticals "sell"Goldman Sachs Group Inc.
21.01.10Bayer DowngradeMorgan Stanley
27.01.09Pfizer reduzierenIndependent Research GmbH
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Pfizer Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen
Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"

AKTIEN IN DIESEM ARTIKEL

Pfizer Inc.17,74
-0,30%
Pfizer Jahreschart

ANZEIGE

ANZEIGE

Was halten Sie von nutzergenerierten Chartanalysen auf finanzen.net?
Ich würde liebend gerne mein Wissen über Chartanalyse dem Publikum von finanzen.net zur Verfügung stellen.
Ich kenne mich bei Chartanalyse nicht so gut aus, halte nutzergenerierte Chartanalysen aber für einen echten Mehrwert.
Ich halte nichts von den Methoden der Chartanalyse und habe deshalb auch kein Interesse an nutzergenerierten Analysen.
 Abstimmen